Courtesy of Dr. Guillermo Migliaro. In regular clinical practice, overlapping stents are reported in up to 30% of patients undergoing coronary angioplasty, especially due to very long lesions requiring implantation of multiple stents or dissection after the implantation of a first stent. In bare metal stent era, overlapping was associated with unfavorable clinical outcomes...
Courtesy of Dr. Leiva. Bioresorbable scaffolds with drug-eluting stents (bioresorbable vascular scaffolds, BVS) have been added to the list of endovascular treatment options for coronary disease. The ABSORB III trial showed the non-inferiority of this stent type to everolimus-eluting metallic stents as regards target-lesion revascularization (TLR) at one year. However, reports have suggested a higher...
Courtesy of Dr. Agustín Vecchia. The aim of this study was to compare the safety and efficacy of bioresorbable everolimus eluting scaffolds (BVS) vs. everolimus eluting stents (EES) in patients with ischemic heart disease. Medline, Embase, the Cochrane Central Register of Controlled Trials (CENTRAL), was searched for scientific sessions, abstracts, and relevant websites for...
Original Title: Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease. Reference: Stone, M.D. for the ABSORB III Investigators. N Engl J Med 2015;373:1905-1915. The ABSORB III is part of a series of randomized studies that test bioresorbable scaffolds in the clinical practice (ABSORB II, EVERBIO II, ABSORB Japan, and ABSORB IV). 2008 patients were randomized; 60% had...
Original title: Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds. Referencia: Puricel S. et al. J Am Coll Cardiol. 2015 Mar 3;65(8):791-801. The everolimus eluting bioresorbable scaffold (BVS) is effective at treating simple lesions in stable patients but it has yet to be assessed against the best-in-class DES. This study compared BVS performance against...
Original title: Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry. Reference: Capodanno D et al. EuroIntervention. 2014 Jul 18. Epub ahead of print The GHOST-EU registry, that included 1189 patients from 10 European centers between 2011 and 2014, is now the largest registry...
Original title: Incidence and Short-Term Clinical Outcomes of Small Side Branch Occlusion Alter Implantation of an Everolimus-Eluting Bioresorbable Vascular Scaffold Reference: Takashi Muramatsu et al. J Am Coll Cardiol Intv 2013;6:247–57. Small Side Branch Occlusion (SBO) during coronary angioplasty has been associated with periprocedural infarction. Among the factors that cause SBO are carina displacement, plaque displacement and artery...
The two year outcomes of ABSORB III, presented at the scientific sessions of the American College of Cardiology 2017, have shown the bioresorbable scaffold Absorb GT1 (BVS, Abbott Vascular) was associated with increased risk of target vessel failure, compared against the everolimus eluting stent Xience. At 25 months, target vessel failure occurred in 11%...
Courtesy of Dr. Carlos Fava. Drug-eluting stents (DES) have shown mid-term benefit in lesions below the knee (BTK) by reducing the rate of acute occlusion and restenosis in type A and B lesions. However, failure to recover the self-regulatory functions of the local vessel could hinder future revascularization. Drug-eluting bioresorbable scaffolds (BVS) could be a solution to this problem....
This work reports one year outcomes of the BVS Expand registry. Multiple studies have shown the safety and feasibility of the everolimus eluting bioresorbable scaffold ABSORB (Abbott Vascular, Santa Clara, California), but medium and long term data are limited and only on simple lesions. This is a prospective single-center registry assessing ABSORB performance in...